Literature DB >> 12680740

The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

Z Abdul-Monim1, G P Reynolds, J C Neill.   

Abstract

The glutamate/N-methyl-D-aspartate receptor antagonist phencyclidine (PCP) has been shown to induce both positive and negative symptoms of schizophrenia, as well as cognitive deficits, thus providing a relatively valid model of psychosis. Isolation rearing from weaning in the rat has been proposed as a non-pharmacological model of psychosis. The aim of the present study was to explore the validity of a combination of these techniques to model cognitive dysfunction associated with schizophrenia. The present study evaluates the effects of the novel antipsychotic ziprasidone and the typical antipsychotic haloperidol in their ability to reverse the cognitive deficit induced by PCP in isolation reared rats and social controls. Rats housed in social isolation (n = 25) or in groups of five (n = 25) from weaning were food deprived and trained to respond for food in an operant reversal learning paradigm. PCP at 1.0 and 1.5 mg/kg (intraperitoneally, i.p.) significantly and selectively impaired reversal task performance in both groups of rats. This impairment was not significantly improved following the coadministration of haloperidol (0.05 mg/kg, i.p.). Higher haloperidol doses (0.1 and 0.25 mg/kg, i.p.) were found to impair task performance, with the social animals being more sensitive than isolation-reared animals. In contrast, ziprasidone (2.5 mg/kg, i.p.) reversed the impairment caused by PCP. This was significant in social animals, while in isolates there was a non-significant enhancement in performance of the reversal task with ziprasidone compared to PCP alone. Thus, PCP produced a selective reversal learning deficit in rats, which was ameliorated following treatment with ziprasidone but not haloperidol. Rearing conditions did not influence performance of the test or the deficit produced by PCP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680740     DOI: 10.1177/0269881103017001700

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  39 in total

1.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

2.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

3.  A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists.

Authors:  Sophie Dix; Gary Gilmour; Slavinka Potts; Janice W Smith; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

4.  Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine.

Authors:  John D Elsworth; Bret A Morrow; Tibor Hajszan; Csaba Leranth; Robert H Roth
Journal:  Neuropsychopharmacology       Date:  2011-06-15       Impact factor: 7.853

Review 5.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

6.  Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in rats.

Authors:  Natashia Swalve; Michele M Mulholland; Tiffany D Schulz; Ming Li
Journal:  Behav Pharmacol       Date:  2016-06       Impact factor: 2.293

Review 7.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

8.  Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia.

Authors:  Jonathan L Brigman; Carolyn Graybeal; Andrew Holmes
Journal:  Front Neurosci       Date:  2010-05-15       Impact factor: 4.677

9.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

Authors:  Samantha L McLean; Marie L Woolley; Dave Thomas; Joanna C Neill
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

10.  Asenapine effects in animal models of psychosis and cognitive function.

Authors:  Hugh M Marston; Jared W Young; Frederic D C Martin; Kevin A Serpa; Christopher L Moore; Erik H F Wong; Lisa Gold; Leonard T Meltzer; Marc R Azar; Mark A Geyer; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2009-05-22       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.